Clinical Trial

Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the long-term safety and tolerability of Admilparant in participants who completed participation in parent studies IM027-068 (for idiopathic pulmonary fibrosis (IPF)) and IM027-1015 (for progressive pulmonary fibrosis (PPF)).
Protocol Amendment History 4 changes
notable Trial sites expanded: 272 -> 275 locations 2026-06-17
notable Trial sites expanded: 216 -> 272 locations 2026-06-03
notable Trial sites expanded: 162 -> 216 locations 2026-05-12
notable Trial sites expanded: 111 -> 162 locations 2026-04-07
Trial Details
NCT Number NCT07441408
Lead Sponsor Bristol-Myers Squibb
Conditions Pulmonary Fibrosis
Enrollment 2,380 participants
Start Date 2026-12-16
Primary Completion 2029-11-22 (estimated)
Study Completion 2030-03-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-14